PersonalisPSNL
PSNL
About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Employees: 225
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
510% more capital invested
Capital invested by funds: $25.8M [Q2] → $158M (+$132M) [Q3]
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
20% more funds holding
Funds holding: 69 [Q2] → 83 (+14) [Q3]
12.59% more ownership
Funds ownership: 42.52% [Q2] → 55.11% (+12.59%) [Q3]
39% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 28
60% less call options, than puts
Call options by funds: $183K | Put options by funds: $459K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7.25
48%
upside
Avg. target
$9.08
86%
upside
High target
$11
125%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Thomas Flaten 9% 1-year accuracy 1 / 11 met price target | 84%upside $9 | Buy Maintained | 8 Jan 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 34% 1-year accuracy 63 / 188 met price target | 125%upside $11 | Buy Maintained | 8 Jan 2025 |
Needham Mike Matson 52% 1-year accuracy 64 / 122 met price target | 48%upside $7.25 | Buy Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 3 articles about PSNL published over the past 30 days
Positive
Zacks Investment Research
3 hours ago
Personalis (PSNL) Upgraded to Buy: Here's Why
Personalis (PSNL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Business Wire
1 week ago
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London's Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer Research UK, co-authors Black and Bartha et al. highlight advancements in lung cancer detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect.
Neutral
Business Wire
1 week ago
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance. Preliminary Full Year 2024 Revenue Revenue of approximately $84.6 million for the full year of 2024 compared with $73.5 million for the full year of 2023, an increase of 15%, and above the company's previous full year guidance range of $83.0.
Neutral
Business Wire
1 month ago
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company's business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis' ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen.
Neutral
Business Wire
1 month ago
Personalis and Tempus Expand Collaboration to Biopharma
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD pr.
Neutral
Business Wire
2 months ago
Personalis to Participate at Upcoming Investor Conferences
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Fireside Chat Time: 12:30 pm Eastern Time Location: The Lotte New York Palace in New York, NY TD Cowen Diagnosing Tomorrow: Tools & Technologies for the Next Decade Date: Thursday, December 12, 202.
Neutral
Seeking Alpha
2 months ago
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.
Neutral
Business Wire
2 months ago
Personalis Reports Third Quarter 2024 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent business accomplishments. Recent Business Accomplishments Raised approximately $35.0 million in net financing proceeds from Tempus AI, Inc. (Tempus), consisting of $18.4 million from Tempus' exercise of all its common stock warrants, at an average price of $2.00 per share, and.
Neutral
Business Wire
2 months ago
Personalis to Present at the Stifel 2024 Healthcare Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19, at 10:55 a.m. Eastern Time in New York, NY at the Lotte New York Palace Hotel. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer mana.
Charts implemented using Lightweight Charts™